Current Investments
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL
Immune Targeting Systems Ltd.
Carlton Brown, London, UK
http://www.its-innovation.co.uk
Immune Targeting System Ltd. is a London based vaccine company developing vaccines for mutating viruses. Its innovative synthetic T cell platform allows to develop novel vaccines for the prevention and treatment of major life-threatening viral infections of global impact, including pandemic and seasonal influenza.
Intellikine, Inc.
Troy Wilson, San Diego, CA, USA
Intellikine develops novel oral small molecules in the PI3K/mTOR pathway with a focus on Oncology and Immunology.
Intradigm Corporation (merged, now Silence Therapeutics)
Mohammad Azab, Palo Alto, CA, US
Intradigm is developing siRNA- derived cancer therapeutics utilizing its proprietary RNAi delivery technology. The company’s lead product ICS-283 is an anti-angiogenic VEGF-targeted cancer therapeutic using the company’s proprietary RNAi delivery technology.